Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy von Kirschner, Tonia, Müller, Matthias P., Rauh, Daniel

Volltext

Molecular control of Rab activity by GEFs, GAPs and GDI von Müller, Matthias P, Goody, Roger S

Volltext

Augmented Reality in Scientific PublicationsTaking the Visualization of 3D Structures to the Next Level von Wolle, Patrik, Müller, Matthias P, Rauh, Daniel

Volltext

Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity von Quambusch, Lena, Landel, Ina, Depta, Laura, Weisner, Jörn, Uhlenbrock, Niklas, Müller, Matthias P., Glanemann, Franziska, Althoff, Kristina, Siveke, Jens T., Rauh, Daniel

Volltext

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS -Mutant Pancreatic and Colorectal Cancer von Weisner, Jörn, Landel, Ina, Reintjes, Christoph, Uhlenbrock, Niklas, Trajkovic-Arsic, Marija, Dienstbier, Niklas, Hardick, Julia, Ladigan, Swetlana, Lindemann, Marius, Smith, Steven, Quambusch, Lena, Scheinpflug, Rebekka, Depta, Laura, Gontla, Rajesh, Unger, Anke, Müller, Heiko, Baumann, Matthias, Schultz-Fademrecht, Carsten, Günther, Georgia, Maghnouj, Abdelouahid, Müller, Matthias P, Pohl, Michael, Teschendorf, Christian, Wolters, Heiner, Viebahn, Richard, Tannapfel, Andrea, Uhl, Waldemar, Hengstler, Jan G, Hahn, Stephan A, Siveke, Jens T, Rauh, Daniel

Volltext

KRasG12C inhibitors in clinical trials: a short historical perspective von Goebel, Lisa, Müller, Matthias P, Goody, Roger S, Rauh, Daniel

Volltext

Bacterial Pathogens Commandeer Rab GTPases to Establish Intracellular Niches von Stein, Mary‐Pat, Müller, Matthias P., Wandinger‐Ness, Angela

Volltext

Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands von Niggenaber, Janina, Heyden, Leonie, Grabe, Tobias, Müller, Matthias P, Lategahn, Jonas, Rauh, Daniel

Volltext

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors von Lategahn, Jonas, Tumbrink, Hannah L., Schultz-Fademrecht, Carsten, Heimsoeth, Alena, Werr, Lisa, Niggenaber, Janina, Keul, Marina, Parmaksiz, Fatma, Baumann, Matthias, Menninger, Sascha, Zent, Eldar, Landel, Ina, Weisner, Jörn, Jeyakumar, Kirujan, Heyden, Leonie, Russ, Nicole, Müller, Fabienne, Lorenz, Carina, Brägelmann, Johannes, Spille, Inga, Grabe, Tobias, Müller, Matthias P., Heuckmann, Johannes M., Klebl, Bert M., Nussbaumer, Peter, Sos, Martin L., Rauh, Daniel

Volltext

Augmented Reality in Scientific Publications – Taking the Visualization of 3D Structures to the Next Level von Wolle, Patrik, Müller, Matthias P, Rauh, Daniel

Volltext

Optimization of Covalent MKK7 Inhibitors via Crude Nanomole-Scale Libraries von Gehrtz, Paul, Marom, Shir, Bührmann, Mike, Hardick, Julia, Kleinbölting, Silke, Shraga, Amit, Dubiella, Christian, Gabizon, Ronen, Wiese, Jan N., Müller, Matthias P., Cohen, Galit, Babaev, Ilana, Shurrush, Khriesto, Avram, Liat, Resnick, Efrat, Barr, Haim, Rauh, Daniel, London, Nir

Volltext

Try Me: Promiscuous Inhibitors Still Allow for Selective Targeted Protein Degradation von Müller, Matthias P., Rauh, Daniel

Volltext

Cellular model system to dissect the isoform-selectivity of Akt inhibitors von Quambusch, Lena, Depta, Laura, Landel, Ina, Lubeck, Melissa, Kirschner, Tonia, Nabert, Jonas, Uhlenbrock, Niklas, Weisner, Jörn, Kostka, Michael, Levy, Laura M., Schultz-Fademrecht, Carsten, Glanemann, Franziska, Althoff, Kristina, Müller, Matthias P., Siveke, Jens T., Rauh, Daniel

Volltext

2-Azo-, 2-diazocine-thiazols and 2-azo-imidazoles as photoswitchable kinase inhibitors: limitations and pitfalls of the photoswitchable inhibitor approach von Schehr, Miriam, Ianes, Chiara, Weisner, Jörn, Heintze, Linda, Müller, Matthias P, Pichlo, Christian, Charl, Julia, Brunstein, Elena, Ewert, Julia, Lehr, Marc, Baumann, Ulrich, Rauh, Daniel, Knippschild, Uwe, Peifer, Christian, Herges, Rainer

Volltext

Targeting Her2-insYVMA with Covalent InhibitorsA Focused Compound Screening and Structure-Based Design Approach von Lategahn, Jonas, Hardick, Julia, Grabe, Tobias, Niggenaber, Janina, Jeyakumar, Kirujan, Keul, Marina, Tumbrink, Hannah L, Becker, Christian, Hodson, Luke, Kirschner, Tonia, Klövekorn, Philip, Ketzer, Julia, Baumann, Matthias, Terheyden, Susanne, Unger, Anke, Weisner, Jörn, Müller, Matthias P, van Otterlo, Willem A. L, Bauer, Sebastian, Rauh, Daniel

Volltext

Design and synthesis of Nrf2-derived hydrocarbon stapled peptides for the disruption of protein-DNA-interactions von Wiedemann, Bianca, Kamps, Dominic, Depta, Laura, Weisner, Jörn, Cvetreznik, Jana, Tomassi, Stefano, Gentz, Sascha, Hoffmann, Jan-Erik, Müller, Matthias P, Koch, Oliver, Dehmelt, Leif, Rauh, Daniel

Volltext

Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines von Grabe, Tobias, Jeyakumar, Kirujan, Niggenaber, Janina, Schulz, Tom, Koska, Sandra, Kleinbölting, Silke, Beck, Michael Edmund, Müller, Matthias P., Rauh, Daniel

Volltext

Assays for Nucleotide Competitive Reversible and Irreversible Inhibitors of Ras GTPases von Jeganathan, Sadasivam, Müller, Matthias P, Ali, Imtiaz, Goody, Roger S

Volltext

Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity von Müller, Matthias P., Jeganathan, Sadasivam, Heidrich, Angelika, Campos, Jeremy, Goody, Roger S.

Volltext

Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors von Goebel, Lisa, Kirschner, Tonia, Koska, Sandra, Rai, Amrita, Janning, Petra, Maffini, Stefano, Vatheuer, Helge, Czodrowski, Paul, Goody, Roger S, Müller, Matthias P, Rauh, Daniel

Volltext